COMPANY PROFILE

Catalym

Developing innovative immunotherapies to transform cancer patients’ lives by effectively engaging their own immune systems to combat this malignant disease

Munich, GermanyFounded 2016Biotech & Life Sciences

Valuation $500M–1B Latest valuation · 2024

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Catalym

CatalYm is a biotech startup that operates in the field of cancer immunotherapy. The company is focused on developing innovative treatments to overcome resistance to immunotherapy in cancer patients. CatalYm's primary product is a monoclonal antibody called visugromab, which targets a protein called GDF-15. This protein is known to inhibit the immune system's response to cancer, making it harder for existing treatments to work effectively. By neutralizing GDF-15, CatalYm aims to enhance the effectiveness of immunotherapy and provide a new treatment option for cancer patients who have not responded to other therapies.

Read full description

CatalYm's business model revolves around the research, development, and commercialization of visugromab. The company generates revenue by conducting clinical trials and, upon successful completion, selling the drug to healthcare providers. CatalYm's target market is the vast number of cancer patients who do not benefit from current immunotherapy treatments due to primary or secondary resistance mechanisms.

The company's entrepreneurial team, backed by strong financial support from shareholders, is committed to exploring the potential of reversing GDF-15-mediated immunosuppression. This approach could pave the way for innovative combination therapies for cancer patients with high unmet needs.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Munich, Germany
Employees: 58
Open positions: 8
Dealroom signal: 67.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Catalym.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES DOther financing	Jul 2024	$150M	$600M	Omega Funds · Novartis Venture Fund · Jeito Capital · Canaan	↗
SERIES COther financing	Nov 2022	$55M	$220M	Bayern Kapital · Coparion · Brandon Capital Partners · Jeito Capital	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Catalym website traffic

Latest recorded traffic for Catalym is 710 monthly website visits, down 69.1% over the last three months. Catalym's team declined 3.3% over the past year.

Latest monthly visits710 3-month web change-69.1% 1-year team growth-3.3%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Clinical Biomarker Operations Specialist (m/f/d)Erika-Mann-Straße, Munich, Bavaria, Germany · Other · Jul 29, 2026 Clinical Biomarker Operations Specialist (m/f/d)Krailling, Bavaria, Germany · Other · Jul 28, 2026 Clinical Development and Operations Support (f/d/m)Krailling, Bavaria, Germany · Other · Jul 14, 2026 Accounts Payable Specialist / Kreditorenbuchhalter (f/x/m)Krailling, Bavaria, Germany · Accounting · Feb 24, 2026 Team Lead - Quality Assurance (m/f/d)- CatalYm GmbHErika-Mann-Straße, Munich, Bavaria, Germany · CSM & Support · Oct 28, 2025 Life Scientist as Team Lead (m/f/d)- CatalYm GmbHErika-Mann-Straße, Munich, Bavaria, Germany · Other · Oct 28, 2025 Supply Chain Manager as Clinical Trial Supply Manager (m/f/d)- CatalYm GmbHErika-Mann-Straße, Munich, Bavaria, Germany · Logistics · Oct 28, 2025

7 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational	19	$60M	$240M
DPDISCO PharmaceuticalsBiotechnological research as well as the development, production and distribution of biotechnological products and solutions of all kinds	Cologne, Germany	Operational
BTBAKX TherapeuticsWe create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations	Kingston, United States	Closed
ITInterline TherapeuticsLeveraging advances in genomics, proteomics, and computational chemistry to identify new medicines	San Francisco, United States	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
EXExogeneBiotechnology company accelerating target and TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening	Oxford, United Kingdom	Operational
EBEisbach BioInnovative start-up in biotechnology developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes	Planegg, Germany	Operational
ABAro BiotherapeuticsFocused on the development of a new protein drug platform	Philadelphia, United States	Operational